Hi shocks, I think this was purely BLT sick of waiting for Biomics to progress it. I just don't think they had the expertise to take it to mouse trials. This has been a pretty expensive lesson and I suspect that the price BLT paid to get 100% ownership was probably already laid out in the original licence agreement. Lets just say that I don't think that collaborating with Chinese biotechs again is going to be in BLT's future.
The important thing is that David Suhy and Mick Graham (now US based) have been working on the program for 12 months and think it is worth buying it back. This is not exactly small change for BLT's.
But hey, you never know. I always thought that Pfizer would be looking pretty closely at this HBV trial given it's involvement with TT-034.
BLT Price at posting:
77.0¢ Sentiment: Hold Disclosure: Held
